120 related articles for article (PubMed ID: 9524924)
21. The role of endogenous nitric oxide in the sympathetic and hemodynamic response to platelet activating factor-induced hypotension in anesthetized dogs.
Wang HG; Shibamoto T; Matsuda Y; Koyama S
Shock; 1998 Jan; 9(1):58-64. PubMed ID: 9466475
[TBL] [Abstract][Full Text] [Related]
22. Assessment of ability of levcromakalim and sodium nitroprusside to reverse the cardiovascular effects of nitric oxide synthase inhibition in the anaesthetised pig.
Herity NA; Allen JD; Silke B; Adgey AA
Cardiovasc Res; 1994 Jun; 28(6):894-900. PubMed ID: 7522965
[TBL] [Abstract][Full Text] [Related]
23. Role of NO and PAF in the impairment of skeletal muscle contractility induced by TNF-alpha.
Alloatti G; Penna C; Mariano F; Camussi G
Am J Physiol Regul Integr Comp Physiol; 2000 Dec; 279(6):R2156-63. PubMed ID: 11080081
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide (NO) modulation of PAF-induced cardiopulmonary action: interaction between NO synthase and cyclo-oxygenase-2 pathways.
Fabi F; Calabrese R; Stati T; del Basso P
Br J Pharmacol; 2001 Oct; 134(4):777-88. PubMed ID: 11606318
[TBL] [Abstract][Full Text] [Related]
25. Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis.
McVeigh GE; Allen PB; Morgan DR; Hanratty CG; Silke B
Clin Sci (Lond); 2001 Apr; 100(4):387-93. PubMed ID: 11256976
[TBL] [Abstract][Full Text] [Related]
26. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
[TBL] [Abstract][Full Text] [Related]
27. Effects of platelet-activating factor on arteriolar and venular tone in rat trachea.
Collins LC; Roberts AM
Microvasc Res; 1997 Jan; 53(1):63-72. PubMed ID: 9056476
[TBL] [Abstract][Full Text] [Related]
28. Role of Nitric oxide in the renal and systemic vasodilatory responses to platelet-activating factor in the rat, in vivo.
Handa RK; Strandhoy JW; Handa SE
Kidney Blood Press Res; 2003; 26(3):165-75. PubMed ID: 12886044
[TBL] [Abstract][Full Text] [Related]
29. Hypoxic pulmonary vasoconstriction in isolated blood-perfused rat lung; modulation by thromboxane A2, platelet-activating factor, cysteinyl leukotrienes and endothelin-1.
Chłopicki S; Bartuś JB; Gryglewski RJ
Pol J Pharmacol; 2002; 54(5):433-41. PubMed ID: 12593530
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of leukotriene B4-induced increase in intracellular calcium ion level of human peripheral blood polymorphonuclear leukocytes by Y-24180, an antagonist of platelet-activating factor receptor.
Komatsu H; Amano M
Int J Immunopharmacol; 1997; 19(11-12):661-7. PubMed ID: 9669206
[TBL] [Abstract][Full Text] [Related]
31. Interactions of pro-inflammatory and vasoactive mediators with nitric oxide in the regulation of rat vascular permeability during laparotomy.
Pávó I; Pozsár J; Morschl E; Nemcsik J; László F; Whittle BJ
Eur J Pharmacol; 2000 Aug; 402(1-2):193-7. PubMed ID: 10940373
[TBL] [Abstract][Full Text] [Related]
32. Platelet-activating factor: the effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis.
Steil AA; Garcia Rodriguez MC; Alonso A; Crespo MS; Bosca L
Br J Pharmacol; 1995 Feb; 114(4):895-901. PubMed ID: 7539698
[TBL] [Abstract][Full Text] [Related]
33. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways.
Gélinas DS; Bernatchez PN; Rollin S; Bazan NG; Sirois MG
Br J Pharmacol; 2002 Dec; 137(7):1021-30. PubMed ID: 12429574
[TBL] [Abstract][Full Text] [Related]
34. The role of platelet-activating factor (PAF) antagonists and nitric oxide in cardiac actions of PAF. Electrophysiological and morphological study.
Kecskeméti V; Balogh I
J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):723-35. PubMed ID: 11192945
[TBL] [Abstract][Full Text] [Related]
35. Nitric oxide mediates platelet activating factor-induced microvascular leakage in rat airways.
Jeon SY; Kim EA; Ma YW; Kim JP; Jung TG; Hwang EG
Ann Otol Rhinol Laryngol; 2001 Jan; 110(1):83-6. PubMed ID: 11201815
[TBL] [Abstract][Full Text] [Related]
36. The vasoconstrictor effects of L-NAME, a nitric oxide synthase inhibitor, in pregnant rabbits.
Losonczy G; Mucha I; Müller V; Kriston T; Ungvári Z; Tornóci L; Rosivall L; Venuto R
Br J Pharmacol; 1996 Jun; 118(4):1012-8. PubMed ID: 8799576
[TBL] [Abstract][Full Text] [Related]
37. Effects of prostaglandins and nitric oxide on the renal effects of angiotensin II in the anaesthetized rat.
Clayton JS; Clark KL; Johns EJ; Drew GM
Br J Pharmacol; 1998 Aug; 124(7):1467-74. PubMed ID: 9723960
[TBL] [Abstract][Full Text] [Related]
38. Possible involvement of endothelium-derived hyperpolarizing factor (EDHF) in the depressor responses to platelet activating factor (PAF) in rats.
Tanaka Y; Hayakawa S; Imai T; Akutsu A; Hirano H; Tanaka H; Nakahara T; Ishii K; Shigenobu K
Br J Pharmacol; 2000 Nov; 131(6):1113-20. PubMed ID: 11082118
[TBL] [Abstract][Full Text] [Related]
39. A platelet-activating factor antagonist (WEB 2170) preserves endothelium-dependent vasodilatation and prevents development of a neo-intima induced by a periarterial collar in rabbit carotid arteries.
Yin ZL; Hickey H; Dusting GJ
J Vasc Res; 1998; 35(3):156-64. PubMed ID: 9647329
[TBL] [Abstract][Full Text] [Related]
40. Role of eicosanoids but not nitric oxide in the platelet-activating factor-induced increase in vascular permeability in mouse skin.
Fujii E; Irie K; Uchida Y; Ohba K; Muraki T
Eur J Pharmacol; 1995 Feb; 273(3):267-72. PubMed ID: 7537684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
